Dominique Salmon

Summary

Country: France

Publications

  1. pmc First observation in a non-endemic country (Togo) of Penicillium marneffei infection in a human immunodeficiency virus-infected patient: a case report
    Akouda Akessiwe Patassi
    Division de l Epidémiologie, Ministere de la Sante, BP 1396 Lomé, Togo
    BMC Res Notes 6:506. 2013
  2. pmc Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Dominique Salmon-Ceron
    Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
    BMC Health Serv Res 12:59. 2012
  3. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
  4. pmc Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
  5. doi request reprint Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    Dominique Salmon-Ceron
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Cochin, France
    AIDS 24:2211-23. 2010
  6. doi request reprint Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study
    Dominique Salmon-Ceron
    Infectious Diseases, Internal Medicine Department, Hopital Cochin, Universite Paris Descartes, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    J Hepatol 50:736-45. 2009
  7. pmc Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    PLoS ONE 2:e725. 2007
  8. pmc Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study
    Gilles Pialoux
    APHP, Tenon Hospital, Paris, France
    Clin Vaccine Immunol 15:562-8. 2008
  9. ncbi request reprint Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy
    Murielle Mary-Krause
    INSERM, UMRS 720 and Université Pierre et Marie Curie, Paris, France
    AIDS 20:1627-35. 2006
  10. ncbi request reprint Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol
    Dominique Salmon-Ceron
    Internal Medicine Department, Cochin Hospital, Paris, France
    J Hepatol 42:799-805. 2005

Detail Information

Publications42

  1. pmc First observation in a non-endemic country (Togo) of Penicillium marneffei infection in a human immunodeficiency virus-infected patient: a case report
    Akouda Akessiwe Patassi
    Division de l Epidémiologie, Ministere de la Sante, BP 1396 Lomé, Togo
    BMC Res Notes 6:506. 2013
    ..We report a case of Penicillium marneffei infection with fatal outcome in a Togolese woman infected with Human Immunodeficiency Virus (HIV)...
  2. pmc Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)
    Dominique Salmon-Ceron
    Unité de maladies infectieuses, Pôle Médecine, Hopital Cochin, Paris, France
    BMC Health Serv Res 12:59. 2012
    ..Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population...
  3. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  4. pmc Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
    ....
  5. doi request reprint Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    Dominique Salmon-Ceron
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Cochin, France
    AIDS 24:2211-23. 2010
    ..Whether HIV-LIPO-5 immunogenicity varies with the dose is unknown...
  6. doi request reprint Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study
    Dominique Salmon-Ceron
    Infectious Diseases, Internal Medicine Department, Hopital Cochin, Universite Paris Descartes, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    J Hepatol 50:736-45. 2009
    ..We describe the proportion of liver-related deaths among HIV-infected patients in 2005 compared with 2000...
  7. pmc Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    PLoS ONE 2:e725. 2007
    ..The objective was to compare the safety and cellular immunogenicity of intradermal versus intramuscular immunization with an HIV-lipopeptide candidate vaccine (LIPO-4) in healthy volunteers...
  8. pmc Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study
    Gilles Pialoux
    APHP, Tenon Hospital, Paris, France
    Clin Vaccine Immunol 15:562-8. 2008
    ..Despite the lack of a control arm, these findings warrant a randomized study of therapeutic vaccination with HIV lipopeptides followed by long-term HAART interruption in AIDS-free chronically infected patients...
  9. ncbi request reprint Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy
    Murielle Mary-Krause
    INSERM, UMRS 720 and Université Pierre et Marie Curie, Paris, France
    AIDS 20:1627-35. 2006
    ..Osteonecrosis was increasingly associated with HIV infection in the 1990s. It is unclear whether its risk increases with the duration of HIV infection, the duration of combination antiretroviral therapy (cART) or both...
  10. ncbi request reprint Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol
    Dominique Salmon-Ceron
    Internal Medicine Department, Cochin Hospital, Paris, France
    J Hepatol 42:799-805. 2005
    ..We analyzed the characteristics of HIV infected patients who died from liver disease, focusing on hepatitis virus co-infection...
  11. doi request reprint Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH
    Dominique Salmon
    Service des Maladies Infectieuses et Tropicales, Hopital Cochin, AP HP, Universite Paris Descartes, Paris, France
    J Hepatol 56:862-8. 2012
    ..The aim of this study was to identify factors predictive of HCC occurrence in a large cohort of HIV/HCV-co-infected patients with cirrhosis...
  12. doi request reprint [Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases]
    Paula Duchet-Niedziolka
    Centre d Investigation Clinique de Vaccinologie Cochin Pasteur, Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, Assistance Publique Hopitaux de Paris, Paris Cedex 14, France
    Presse Med 38:243-50. 2009
    ..More immunogenic vaccine strategy should be evaluated in patients with systemic autoimmune and/or inflammatory diseases to provide better vaccine coverage...
  13. doi request reprint Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans
    Suzanne Figueiredo
    Inserm U1016, Institut Cochin, Paris, France CNRS UMR8104, Paris, France Univ Paris Descartes, Paris, France
    Vaccine 32:492-501. 2014
    ....
  14. doi request reprint How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
    ....
  15. ncbi request reprint Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals
    Dominique Costagliola
    INSERM U720, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 10:563-73. 2005
    ..To study the prognosis of HIV-infected patients with virological failure after exposure to three classes of antiretroviral drugs (ARVs)...
  16. pmc Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients
    Deborah Hirt
    Service de Pharmacologie Clinique, AP HP, Hopital Cochin Saint Vincent de Paul, Universite Paris Descartes, Paris, France
    Br J Clin Pharmacol 65:548-57. 2008
    ..However, for MDR1 and CYP2C19 polymorphism, there have been contradictory studies, showing either no impact on nelfinavir concentration or modified concentrations which could influence virological response...
  17. doi request reprint A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients
    Marion Bouillon-Pichault
    Universite Paris Descartes, Paris, France
    Antivir Ther 14:923-9. 2009
    ..However, the probability to achieve these target C(troughs) with the current 400 mg twice-daily or 800 mg once-daily doses of the new tablet form, and the influence of body weight on this probability are unknown...
  18. doi request reprint Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Acquir Immune Defic Syndr 49:272-5. 2008
    ..The immunogenicity of vaccines, including vaccine against hepatitis A virus (HAV), is impaired in patients with HIV infection, requiring revised immunization regimens...
  19. doi request reprint Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response
    Firouzé Bani-Sadr
    aUnité des Maladies Infectieuses et Tropicales, Hopital Robert Debre, université Champagne Ardenne, Reims bINSERM, ISPED, Centre INSERM U897 Epidemiologie Biostatistiques, Bordeaux cINSERM, U912 SE4S Université Aix Marseille, IRD, UMR S912 ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d Azur, Marseille dService des Maladies Infectieuses et Tropicales, Groupe Hospitalier Necker Enfants Malades, AP HP, Paris eService des Maladies Infectieuses et Tropicales, Groupe Hospitalier Avicenne, AP HP, Bobigny fService des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard gService des Maladies Infectieuses et Tropicales, Hopital Cochin, APHP Université Paris Descartes, Paris, France
    AIDS 28:1155-60. 2014
    ..The impact of hepatitis C virus (HCV)-related characteristics such as genotype, viral load or liver fibrosis on the chances of achieving sustained HIV suppression in coinfected patients is not fully documented...
  20. ncbi request reprint Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort
    Xavier Duval
    Laboratoire de Recherche en Pathologie Infectieuse, Faculte Xavier Bichat, Paris, France
    Ther Drug Monit 27:63-70. 2005
    ..These data suggest that any strategy of therapeutic drug monitoring must imply first a combined evaluation of plasma concentrations and adherence level and second an intervention target based on the results of both assessments...
  21. ncbi request reprint Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study
    Gilles Pialoux
    APHP, Hopital Tenon, 4 rue de la Chine, Paris Cedex 20, France
    Vaccine 26:2657-66. 2008
    ..No anti-gp160 activity was found between week 4 and week 48 in serum, saliva, or cervicovaginal and nasal secretions. These results show that a mucosal HIV vaccine can be well tolerated when administered by the nasal or vaginal route...
  22. pmc Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial
    Xavier Duval
    Inserm CIC 007, Hopital Bichat, Paris, France
    Fundam Clin Pharmacol 23:491-500. 2009
    ....
  23. ncbi request reprint The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy
    Florence Tubach
    INSERM U738, Bichat Teaching Hospital, Xavier Bichat School of Medicine, Paris 7 University, Paris, France
    Joint Bone Spine 72:456-60. 2005
    ....
  24. ncbi request reprint High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy
    Cecile Goujard
    Internal Medicine Unit, Bicetre University Hospital, AP HP, Kremlin Bicetre, France
    Clin Pharmacokinet 44:1267-78. 2005
    ....
  25. doi request reprint Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir)
    Valérie Bourcier
    Service d Hepato Gastroenterologie, Hopital Jean Verdier, Assistance Publique Hopitaux de Paris, UFR SMBH, Universite Paris 13, 93143 Bondy Cedex, France
    Clin Res Hepatol Gastroenterol 36:214-21. 2012
    ..Our aim was to compare characteristics and outcome of primary liver cancer according to HIV status in HCV cirrhotic patients submitted to periodic ultrasonographic surveillance...
  26. doi request reprint Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000
    Philippe Morlat
    aINSERM, ISPED, Centre INSERM U897 Epidémiologie Biostatistiques bService de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux cUniversity Bordeaux, ISPED, Centre INSERM U897 Epidemiologie Biostatistiques, Bordeaux dService de Maladies Infectieuses, Hopital Brabois, Vandoeuvre Les Nancy eUnité de Pathologie Infectieuse, Pôle Médecine, Hopital Cochin, AP HP fUniversité Paris Descartes gDepartment of Internal Medicine and Immunology, AP HP Hôpital La Pitié Salpêtrière hDépartement Hospitalo universitaire I2B, UPMC Univ Paris 06, UMR 7211, Paris iINSERM CépiDC, Le Kremlin Bicêtre jService de Médecine Interne, Hôpital de l Archet kUniversité de Nice Sophia Antipolis, Nice lService des Maladies Infectieuses et Tropicales, Hopital Purpan, Toulouse mService des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine nUniversité Paris 7 oINSERM, UMR S 1136 pSorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Paris qCHU de Bordeaux, pôle de santé publique, Bordeaux, France
    AIDS 28:1181-91. 2014
    ..The Mortalité 2010 survey aimed at describing the causes of death among HIV-infected patients in France in 2010 and their evolution since 2000...
  27. ncbi request reprint Use of well-defined HIV-derived epitopes to evaluate CD4(+) and CD8(+) T cell responses in patients with chronic HIV-1 infection treated with HAART
    Nathalie Daniel
    Department of Immunology, Cochin Institute, INSERM U567, CNRS UMR 8104, Rene Descartes University, Department of Internal Medicine, Cochin Hospital, Paris, France
    AIDS Res Hum Retroviruses 20:827-35. 2004
    ..In conclusion, the experimental approach used in this study shows that CD4(+) T cell responses may persist during HAART but are not associated with strong CD8(+) T cell responses..
  28. pmc Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
    ....
  29. doi request reprint Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients
    Fabrice Carrat
    UPMC Paris6, UMR S707, INSERM, UMR S707, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, France
    AIDS 22:1513-5. 2008
    ..83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response...
  30. doi request reprint Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections
    Emmanuel Curis
    Laboratoire de Biomathématiques, Faculte de Pharmacie, Universite Paris Descartes, Sorbonne Paris Cité, 4, avenue de l Observatoire, 75006, Paris, France
    Infection 43:473-81. 2015
    ..The aims of the work were to study the determinants of plasma clindamycin trough concentration, C min, especially the effect of co-treatment with rifampicin, and the consequences on clinical outcome...
  31. ncbi request reprint Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults
    Fideline Collin
    INSERM, U593, Bordeaux, France, and ISPED, Universite Victor Segalen Bordeaux 2, ISPED Bordeaux, France
    Ther Drug Monit 29:164-70. 2007
    ..Prospective and early indinavir Cres determination should be recommended in the patient's care management and dosage adjustments...
  32. ncbi request reprint A cohort study of enfuvirtide immunological and virological efficacy in clinical practice
    Boris Bienvenu
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Med Virol 78:1312-7. 2006
    ..However, the mutations conferring resistance to enfuvirtide develop rapidly when viral load is not controlled confirming that enfuvirtide should be prescribed in association with an active background regimen...
  33. ncbi request reprint New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine
    Hanne Gahery
    Institut Cochin, Departement d Immunologie, INSERM U567, CNRS UMR8104, Universite Rene Descartes, 75014 Paris, France
    AIDS Res Hum Retroviruses 22:684-94. 2006
    ..Lipopeptides induce new anti-HIV T cell responses in vaccinated infected patients and could be used as a new immunotherapy strategy. The majority of these responders induced specific new CD4(+) and CD8(+) T cell responses...
  34. doi request reprint Adherence to preventive measures after splenectomy in the hospital setting and in the community
    Hélène Coignard-Biehler
    Paris Descartes University, Paris, France
    J Infect Public Health 4:187-94. 2011
    ..Overwhelming post-splenectomy infection (OPSI) remains a long-term risk in asplenic patients, which may be reduced by appropriate preventive measures. Specific guidelines have been developed to lower its incidence...
  35. ncbi request reprint Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy
    Karine Gourlain
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 69:401-7. 2003
    ....
  36. ncbi request reprint [Antiretroviral agents in HIV-infected patients with cirrhosis]
    Dominique Salmon-Ceron
    Universite Paris V, Faculte Cochin, Service de Maladies Infectieuses, Hospital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Presse Med 34:1S45-52. 2005
    ..In any event rigorous monitoring is a must...
  37. doi request reprint Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression
    Pierre Gantner
    Universite Paris Descartes, EA 7327, Université Paris Descartes PRES Sorbonne Paris Cité, Paris, France Laboratoire de Virologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    J Antimicrob Chemother 71:751-61. 2016
    ..The objective of this study was to address the dynamics of archived resistant quasispecies in cell-associated HIV-1 DNA over time in heavily ART-experienced patients with currently suppressed plasma HIV-1 RNA...
  38. pmc Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
    Haifa Hamdi
    INSERM UMR S764, Service d Hepato gastro enterologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Institut Paris Sud sur les Cytokines, Universite Paris Sud, INSERM U764, 32 rue des Carnets, 92140, Clamart, France
    Arthritis Res Ther 8:R114. 2006
    ..Such a dual effect may explain the increased incidence of TB in patients treated with TNF antagonists as well as possible differences between TNF antagonists for the incidence and the clinical presentation of TB reactivation...
  39. ncbi request reprint Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference
    Dominique Salmon
    Infectious Diseases Unit, Cochin Hospital, Rene Descartes University, Paris V, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    J Hepatol 44:S2-5. 2006
    ..Recently published trials in co-infected patients and the outcome from this Consensus Conference will hopefully lead to wider access to anti-HCV therapy and better management of co-infected patients across Europe...
  40. doi request reprint Encrusting cystitis due to Corynebacterium urealyticum in a patient with ANCA-associated vasculitis: case report and review of the literature
    Christian Pagnoux
    Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Semin Arthritis Rheum 41:297-300. 2011
    ..The relevant literature on this infection is reviewed...
  41. doi request reprint [Tuberculosis risk among patients with systemic diseases]
    Mona Ben M'rad
    Service de Medecine Interne, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Universite de Versailles Saint Quentin en Yvelines, F 92100 Boulogne Billancourt, France
    Presse Med 38:274-90. 2009
    ..The screening strategies for tuberculosis should probably be extended in all patients with systemic rheumatic diseases receiving glucocorticoids and/or immunosuppressive therapy...
  42. doi request reprint [Vaccination in patients with systemic diseases]
    Thomas Hanslik
    Service de Medecine Interne, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Universite de Versailles Saint Quentin en Yvelines, Boulogne Billancourt Cedex, France
    Presse Med 38:235-42. 2009
    ..These findings are an encouragement to properly immunize patients with systemic diseases. Measures should be taken to improve immunization coverage for these patients and their entourage...